Brief: Orchard Therapeutics Reports OTL-201 Initial Clinical Data In Sanfilippo Syndrome Type A
08/12/2020 12:18
Dec 8 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS REPORTS OTL-201 INITIAL CLINICAL DATA
IN
SANFILIPPO SYNDROME TYPE A (MPS-IIIA)
* ORCHARD THERAPEUTICS PLC - TREATMENT WAS GENERALLY
WELL-TOLERATED WITH NO TREATMENT RELATED ADVERSE EVENTS OR
SERIOUS ADVERSE EVENTS TO DATE
* ORCHARD THERAPEUTICS PLC - RESULTS FROM FIRST PATIENT
TREATED
WITH OTL-201 SHOWED PROMISING SAFETY, TOLERABILITY, ENGRAFTMENT
AND BIOMARKER DATA
* ORCHARD THERAPEUTICS PLC - REDUCTION OF URINARY HEPARAN
SULFATE
FROM 60.8 MG/MMOL CREATININE AT BASELINE TO NORMAL RANGE BY 3
MONTHS POST-TREATMENT
* ORCHARD THERAPEUTICS PLC - COMPLETION OF ENROLLMENT AND
RELEASE
OF ADDITIONAL INTERIM RESULTS FROM OTL-201 STUDY ARE EXPECTED IN
2021
Source text for Eikon: ID:nGNX5J9bzP
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln